Avecho Biotechnology Limited (OEZ) - Total Assets
Based on the latest financial reports, Avecho Biotechnology Limited (OEZ) holds total assets worth €7.11 Million EUR (≈ $8.31 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check OEZ total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Avecho Biotechnology Limited - Total Assets Trend (2013–2025)
This chart illustrates how Avecho Biotechnology Limited's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Avecho Biotechnology Limited to evaluate the quality of earnings relative to operating cash generation.
Avecho Biotechnology Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Avecho Biotechnology Limited's total assets of €7.11 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 65.6% |
| Accounts Receivable | €155.98K | 2.2% |
| Inventory | €8.07K | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Avecho Biotechnology Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OEZ company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avecho Biotechnology Limited's current assets represent 99.3% of total assets in 2025, an increase from 34.0% in 2013.
- Cash Position: Cash and equivalents constituted 65.6% of total assets in 2025, up from 21.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 63.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
Avecho Biotechnology Limited Competitors by Total Assets
Key competitors of Avecho Biotechnology Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Avecho Biotechnology Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.95 | 2.81 | 4.46 |
| Quick Ratio | 9.94 | 2.73 | 4.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €6.35 Million | €3.10 Million | €2.09 Million |
Avecho Biotechnology Limited - Advanced Valuation Insights
This section examines the relationship between Avecho Biotechnology Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.88 |
| Latest Market Cap to Assets Ratio | 3.63 |
| Asset Growth Rate (YoY) | 42.2% |
| Total Assets | €7.11 Million |
| Market Capitalization | $25.76 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Avecho Biotechnology Limited's assets at a significant premium (3.63x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Avecho Biotechnology Limited's assets grew by 42.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Avecho Biotechnology Limited (2013–2025)
The table below shows the annual total assets of Avecho Biotechnology Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €7.11 Million ≈ $8.31 Million |
+42.21% |
| 2024-12-31 | €5.00 Million ≈ $5.84 Million |
-31.88% |
| 2023-12-31 | €7.34 Million ≈ $8.58 Million |
+119.25% |
| 2022-12-31 | €3.35 Million ≈ $3.91 Million |
-36.23% |
| 2021-12-31 | €5.25 Million ≈ $6.13 Million |
+56.38% |
| 2020-12-31 | €3.35 Million ≈ $3.92 Million |
-36.89% |
| 2019-12-31 | €5.32 Million ≈ $6.21 Million |
+10.69% |
| 2018-12-31 | €4.80 Million ≈ $5.61 Million |
-41.72% |
| 2017-12-31 | €8.24 Million ≈ $9.63 Million |
-38.30% |
| 2016-12-31 | €13.35 Million ≈ $15.61 Million |
-56.56% |
| 2015-12-31 | €30.74 Million ≈ $35.94 Million |
-39.60% |
| 2014-12-31 | €50.90 Million ≈ $59.51 Million |
+22.10% |
| 2013-12-31 | €41.69 Million ≈ $48.74 Million |
-- |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more